Steven Coca, DO, outlines the importance of early identification of kidney disease in patients with diabetes and the potential to use artificial intelligence for this purpose.
Steven G. Coca, DO
Steven G. Coca, DO, is a graduate of the University of New England College of Osteopathic Medicine. He completed his medical residency and clinical nephrology fellowship at Yale University and Yale New Haven Hospital in Connecticut, and also received a Master’s degree in epidemiology and public health during his training at Yale. There, he later served as an assistant professor in the section of nephrology until his recruitment to Mount Sinai in 2014 as an associate professor. He is the director for clinical research for the division of nephrology and the associate chair for clinical and translational research for the department of medicine at the Icahn School of Medicine at Mount Sinai in New York.
His research has focused on using novel biomarkers to improve risk stratification in patients with acute kidney injury and patients at risk for or with prevalent chronic kidney disease. He has been continually funded by the National Institutes of Health over the last decade for multiple biomarker-related projects. He is the cofounder of RenalytixAI.
